Catherine Martin

发表

Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?

R. Dwek, T. Butters, R. Callaghan, 2006, European journal of pharmacology.

Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models.

M. Hall, D. Ferguson, T. Hambley, 2004, Biochemical pharmacology.

The importance of cholesterol in maintenance of P-glycoprotein activity and its membrane perturbing influence

C. Higgins, R. Callaghan, P. Devaux, 2001, European Biophysics Journal.

Detailed characterization of cysteine‐less P‐glycoprotein reveals subtle pharmacological differences in function from wild‐type protein

K. Linton, C. Higgins, R. Callaghan, 2001, British journal of pharmacology.

The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein

C. Higgins, P. Charlton, R. Callaghan, 1999, British journal of pharmacology.

The multi‐drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P‐glycoprotein by an allosteric interaction

C. Higgins, R. Callaghan, G. Berridge, 1997, British journal of pharmacology.

Repacking of the transmembrane domains of P‐glycoprotein during the transport ATPase cycle

K. Linton, C. Higgins, R. Callaghan, 2001, The EMBO journal.

Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.

R. Callaghan, Catherine Martin, J. Walker, 2004, European journal of cancer.

The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models

R. Callaghan, A. Rothnie, Catherine Martin, 2003, British Journal of Cancer.

Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis.

C. Higgins, P. Charlton, R. Callaghan, 2000, Biochemistry.

Communication between multiple drug binding sites on P-glycoprotein.

C. Higgins, P. Charlton, R. Callaghan, 2000, Molecular pharmacology.